« Return to News | CROs/Service Providers

PPD 3Q Earnings Up, Cuts 2008 Guidance

Wednesday, October 22, 2008 09:04 AM

PPD, a contract research organization (CRO), reported third quarter revenue increased 11.6% to $398.5 compared with $357.2 million for the third quarter of 2007. Diluted earnings per share jumped 34% to $0.43 per share.

The company lowered its full-year revenue projection to between $1.47 billion and $1.49 billion from $1.54 billion to $1.59 billion as a result of a FDA delay in approving diabetes drug alogliptin.

Income from operations for the third quarter rose 35% to $71.3 million. 

New business authorizations for the third quarter amounted to $705  million, a 23.6 percent year-over-year increase. Contract cancellations for the quarter were $207.7 million, for a book-to-bill ratio of 1.36. The company's cancellation rate was 24%. Backlog at Sept. 30 was $3 billion, a year-over-year increase of 20%.

"We were very pleased with the level of new business wins and the rebound from the second quarter," said Fred Eshelman, CEO of PPD. "While third quarter revenue growth was moderately slower than expected, demand for drug development services remains strong, and we believe our new authorizations and existing backlog should help drive future top line sustained growth."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.